Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Merck gets another Vioxx verdict tossed

Executive Summary

Texas appeals court overturns the jury verdict in the first Vioxx case to go to trial, finding "no evidence" that alleged victim Bob Ernst suffered a myocardial infarction triggered by a blood clot. "Accordingly, appellee failed to show that ingestion of Vioxx caused her husband's death," the court rules May 29. In 2005 the jury had awarded the plaintiff $253 million, which was later reduced to $26 million. The same appeals court reversed a $32 million jury verdict against Merck the previous week (1"The Pink Sheet," May 19, 2008, In Brief). Also on May 29, the New Jersey Appellate Division overturned the punitive damages and consumer fraud award in combined cases against Merck while letting stand a compensatory damages award for personal injury. As a result, about $13 million of the $18 million awarded in the McDarby and Cona cases has been overturned

You may also be interested in...



Vioxx verdict tossed

A Texas appellate court reversed a $32 million jury verdict against Merck, finding that there was insufficient evidence that Vioxx caused the heart attack of Leonel Garza Sr. The jury had awarded $7 million in compensatory damages and $25 million in punitive damages, the latter of which was reduced to $750,000. Juries have ruled in favor of Merck 12 times and in favor of plaintiffs five times. With the May 14 ruling reversing one of the five plaintiffs' wins, Merck may have more leverage in negotiating settlements of pending cases

FDA OK’s Insomnia Treatment Through Software Pre-Cert Program

Pear Therapeutics’ Somryst insomnia treatment tool has become the first FDA-cleared product that was reviewed through the agency’s Software Precertification Pilot Program.

Neuraxpharm Allies With Panaxia On Cannabis Portfolio

CNS specialist Neuraxpharm has struck a deal with Israel’s Panaxia to market medical cannabis products in Europe, starting in Germany.

UsernamePublicRestriction

Register

PS049701

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel